NADA

V-arachidonoyl-dopamine (NADA, 27) is an endogenous capsaicin-like substance in mammalian nervous tissues. NADA activates cannabinoid CB, receptors, but not dopamine D1 and D2 receptors (Bezuglov et al., 2001 Bisogno et al., 2000). NADA occurs in nervous tissues, with the highest concentrations being found in the striatum, hippocampus, and cerebellum and the lowest concentrations in the dorsal root ganglion (Chu et al., 2003). Proposed mechanisms of NADA biosynthesis include the condensation of AA with tyrosine and the subsequent conversion of A-arachidonoyl-tyrosine to NADA by tyrosine hydroxylase and L-aromatic amino acid decarboxylase. 

---

Pisani C, Doves R and Nada R 1990 Ab initio Hartree-Fock perturbed-cluster treatment of local defects in crystals J. Chem. Phys. 92 7448... 

Animal dmg controls are similar to those for human dmgs. The sponsor of a new animal dmg must demonstrate both safety and effectiveness of the dmg for a particular intended use before a New Animal Dmg AppHcation (NADA) is approved (24). Manufacturers of generic animal dmgs may submit Abbreviated New Animal Dmg AppHcations (ANADAs), which are comparable to abbreviated new dmg appHcations submitted by manufacturers of human generic dmgs. 

When it approved the New Animal Drug AppHcation (NADA) of formalin, FDA ruled that use of formalin for fisheries was safe for humans and the environment. They ruled that effluents from fish treatments at 250 mg/L should be diluted 10 times and from egg treatments 75 times if 1,000 —2,000 mg/L were used (10,11). Before registering the compound, FDA also addressed carcinogenicity by stating it was not concerned about human exposure from either water or fish treated with formalin. The U.S. Fish and Wildlife Service (USFWS) has procedural guidelines that should protect workers from harm fill levels of formalin. Calculations based on treatment levels demonstrated that a fishery worker is exposed to not more than 0.117 mg/L formalin in the air, well below the levels estabUshed by the U.S. Occupational Safety and Health Administration to protect workers. 

More recently, simulation studies focused on surface melting [198] and on the molecular-scale growth kinetics and its anisotropy at ice-water interfaces [199-204]. Essmann and Geiger [202] compared the simulated structure of vapor-deposited amorphous ice with neutron scattering data and found that the simulated structure is between the structures of high and low density amorphous ice. Nada and Furukawa [204] observed different growth mechanisms for different surfaces, namely layer-by-layer growth kinetics for the basal face and what the authors call a collected-molecule process for the prismatic system. 

Y. Furukawa, H. Nada. Anisotropic surface melting of an ice crystal and its relationship to growth forms. J Phys Chem B 707 6167, 1997. 

H. Nada, Y. Furukawa. Anisotropic growth kinetics of ice crystals from water studied by molecular dynamics simulation. J Cryst Growth 169 581, 1996. 

Debesh Maldas Pulp and Paper Research Center, University of Quebec, Trois-Rivieres, Quebec, Canada Ajit B. Mathur Research Centre, Indian Petrochemicals Corporation Ltd., Baroda, India Metwally ShaHk Metwally Department of Chemistry, Al-Azhar University, Cairo, Egypt Ramazan Mirzaoglu Department of Chemistry, Sel uk University, Konya, Turkey Bhupendra Nath Misra Department of Chemistry, Himachal Pradesh University, Shimla, India Abd-Alla M. A. Nada Cellulose Paper Department, National Research Centre, Cairo, Egypt Susumu Nagai Plastics Technical Society, Osaka, Japan... 

Depending on whether it is classified as a drug or a biologic, the applicant must submit either a New Animal Drug Application (NADA) to the FDA CVM or veterinary biologies licence applications to the USDA CVB. 

The requirements for a NADA are set out in 21 CFR 514.1 and summarised in Figure 7.7. A F DA-35 6v form must accompany each submission (see Figure 7.8). This is similar to the form used for human drug submissions in that it captures basic information on the submission and provides a checklist for accompanying documents or materials. The labelling should include instmetions on how to use the drug in the manufacture of medicated feeds, where such use is intended. The CVM may request samples of the dmg product itself reference materials or standards, and samples of food produce from treated animals in order that they can, in conjunction... 

Sefain MZ, Nada AMA, El-kalyoubi SF (1980) Cellul Chem Technol 14 139... 

---